4 ‐bp insertion/deletion (rs3783553) polymorphism within the 3'UTR of IL1A contributes to the risk of prostate cancer in a sample of Iranian Population
In conclusion, our findings proposed an association between IL1A 4‐bp ins/del polymorphism and PCa risk. Additional studies with enlarged sample size and diverse ethnicities are required to validate our finding. This article is protected by copyright. All rights reserved
At the American Society for Radiation Oncology annual meeting in 2014 in San Francisco, significant excitement rose from a genitourinary oral session in which several abstracts discussed the potential for localized treatment of N1 prostate cancer to change anticipated survival outcomes (1-3). Since then, studies have been published on the utility of treatment for both N1 and true metastatic disease, arguing that prevention of “reseeding” from primary disease or current metastases can reduce future metastases (4).
Authors: Song XF, Chang H, Liang Q, Guo ZF, Wu JW Abstract OBJECTIVE: Prostate cancer is a kind of malignancy with high occurrence in the male urogenital system. However, the mechanism of the occurrence, the progression, and the metastasis of prostate cancer are still unclear. Searching for the effective molecule target is of great significance to improve the curative effect on prostate cancer. Zinc finger E box binding protein-1 (ZEB1) protein is a member of the zinc finger transcription factor family that participates in the embryonic development and formation. ZEB1 was found to be involved in the occurrence and ...
Authors: Lin YL, Li YL, Ma JG Abstract BACKGROUND PCDH8 is a newly-discovered suppressor gene that is frequently inactivated by aberrant methylation in several human cancers, including prostate cancer. The identification of PCDH8 methylation can be used as a potential predictive biomarker. Prostate cancer patients with high Gleason score are considered as being at high risk for tumor recurrence and progression, and adjuvant therapy is often routinely performed in clinical practice. In the present study, we did not measure the methylation of PCDH8 in these patients. The main purpose of the present study was to evalu...
In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with prostate cancer and in patients with ovarian cancer. The Texas-based company’s nanoparticle tech is based on a production process that cuts the size of chemotherapy crystals by up to 400 times, creating stable nanoparticles with increased surface area and unique geometry, NanOlogy explained. The particles do not require coating agents for stability and are suspended prior to use. Get the full story at our sister site, Drug Delivery Business News. The post NanOlogy takes nano...
CONCLUSION: Performance rates of DRE and PSA testing by doctors who are not urologists are very low, which may have significant clinical implications. It is recommended that SA prostate cancer screening guidelines are necessary to change practice with regard to this condition. PMID: 29025456 [PubMed - in process]
ConclusionsDespite significant decrease in RBI volume the high-dose rectal volume and the predicted LRB risk were unaffected due to a persistent spacing between the prostate and the anterior rectal wall.
This article is protected by copyright. All rights reserved.
ConclusionsLR after surgery for bone metastasis to extremities is affected by surgical margin and primary cancer type. These factors, along with expected patient survival, need to be considered when planning surgery for bone metastasis to extremities.
Deebel et al highlight substantial gaps in our understanding of prostate cancer in transgender women. However, clarification and contextualization of terminology and concepts in the article is needed to better serve its purpose of improving care among transgender patients.